Vaksin Penangkal Varian Baru Sudah Mulai Dibuat? - Indra Rudiansyah | Endgame #47

TL;DR

Indra Rudiansyah discusses his journey and vaccine research.

Transcript

Many people say, "When will you come back to Indonesia? Let's develop technology in Indonesia," like that. Instead, we have to start bridging connections between outside institutions, and those that are existing in Indonesia. Indonesia is famous, sir. Indonesian people are strong, sir. Why don't we take advantage of that title for us to become rep... Read More

Key Insights

• Indra Rudiansyah emphasizes the importance of bridging Indonesian institutions with global entities to advance technology and science in Indonesia.
• He shares his journey from a simple family background to becoming a scientist involved in the Oxford-AstraZeneca vaccine development.
• Indra highlights the significance of Indonesia's diaspora in representing the country and fostering international collaborations.
• He explains the differences between DNA and RNA vaccine platforms, and why the AstraZeneca vaccine uses a viral vector approach.
• Indra discusses the noble decision of Oxford not to patent their vaccine findings, making it more affordable and accessible globally.
• He shares insights on the potential of CRISPR technology in treating genetic diseases and the ethical considerations involved.
• Indra envisions Indonesia becoming a hub for biotech innovation by 2045, with startups like Nusantics leading the way.
• He stresses the importance of vaccination in combating COVID-19 and the need for a robust surveillance system to prevent future pandemics.

Questions & Answers

Q: What is Indra Rudiansyah's view on the role of Indonesian diaspora?

Indra Rudiansyah believes that the Indonesian diaspora plays a crucial role in bridging international institutions with those in Indonesia. He sees them as representatives who can foster collaborations and bring advanced technology and knowledge to the country. By doing so, Indonesia can catch up with global advancements more effectively.

Q: Why does the AstraZeneca vaccine use a viral vector approach?

The AstraZeneca vaccine uses a viral vector approach because it is more straightforward and feasible given the current technological resources. At the time of its development, mRNA platforms were still difficult to apply due to stability issues. The viral vector method, using chimpanzee adenovirus, provides a flexible and effective platform for rapid vaccine development against emerging diseases.

Q: What is the significance of Oxford not patenting their vaccine findings?

Oxford's decision not to patent their vaccine findings is significant because it allows the AstraZeneca vaccine to be produced and sold at a lower cost, making it more accessible worldwide. This approach prioritizes public health over profit, ensuring that even low-income countries can afford the vaccine, which is crucial for global pandemic control.

Q: How does Indra Rudiansyah view the future of CRISPR technology?

Indra Rudiansyah sees CRISPR technology as a double-edged sword. While it holds great potential for treating genetic diseases and improving human health, it also poses ethical challenges. The technology could be misused for non-therapeutic purposes, such as eugenics. Therefore, it is vital to establish ethical guidelines and policies to ensure its responsible use.

Q: What are Indra Rudiansyah's predictions for Indonesia in 2045?

Indra Rudiansyah envisions Indonesia as a biotech hub by 2045, similar to Silicon Valley. He believes that with the growth of startups like Nusantics and Nalagenetics, Indonesia can become a leader in health technology and innovation. The country's large population and market potential make it an attractive place for biotech development.

Q: What is Indra Rudiansyah's stance on COVID-19 vaccination?

Indra Rudiansyah strongly advocates for COVID-19 vaccination, emphasizing that it is essential to achieving herd immunity and ending the pandemic. He encourages people to get vaccinated with any available vaccine, as all vaccines provide protection against the virus. Increasing vaccination rates is crucial to preventing further mutations and controlling the spread of COVID-19.

Q: How does Indra Rudiansyah suggest Indonesia can catch up with global scientific advancements?

Indra Rudiansyah suggests that Indonesia can catch up with global scientific advancements by fostering collaborations with international institutions. By sharing data and resources, Indonesian scientists can benefit from global expertise and technology. He also highlights the importance of the diaspora in facilitating these collaborations and bringing knowledge back to Indonesia.

Q: What is Indra Rudiansyah's message for the future of Indonesia?

Indra Rudiansyah's message for the future of Indonesia is one of confidence and collaboration. He urges all sectors—individuals, government, and private entities—to work together to overcome COVID-19 and prepare for future challenges. He emphasizes learning from past experiences to build a resilient system that can handle new pandemics and improve public health.

Summary & Key Takeaways

• Indra Rudiansyah, an Indonesian scientist, discusses his journey from a simple family to being part of the Oxford-AstraZeneca vaccine team. He highlights the importance of international collaboration to advance science in Indonesia.

• Indra explains the differences between DNA and RNA vaccine platforms and why the AstraZeneca vaccine uses a viral vector approach. He also discusses the ethical implications of CRISPR technology in genetic modification.

• Indra envisions Indonesia becoming a biotech hub by 2045, driven by startups like Nusantics. He emphasizes the importance of vaccination and robust surveillance systems to combat COVID-19 and prevent future pandemics.